Noradrenaline, psychotic decompensation, and drug response in schizophrenia

  • D. P. van Kammen
  • T. C. Neylan
  • W. B. van Kammen
  • J. L. Peters
  • J. Rosen
  • M. Linnoila


Recent Biological investigation in schizophrenia has revealed a role for noradrenaline (NA). Disturbed noradrenergic activity is among the most replicated biological findings in schizophrenia. Increased NA levels have been found in CSF, autopsy brains, and plasma. For review see Hornykiewicz [1] and van kammen and Antelman [2]. However, not all investigators have demonstrated increased NA indices of activity. CSF NA has been found to be highly variable from LP to LP, in contrast to CSF MHPG, HVA and 5HIAA [3]. Alpha-2 receptor functions has been found to be both increased [4–6] and decreased [7–9]. This confusing variability of results left some investigators to conclude that the noradrenergetic system was not disturbed in schizophrenia [10].


Negative Symptom Schizophrenic Patient Psychotic Episode Haloperidol Treatment Noradrenergic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hornykiewicz, O (1982). Brain catecholamines in schizophrenia - a good case for noradrenalines.Nature, 299,484PubMedCrossRefGoogle Scholar
  2. 2.
    van Kammen, DP and Antelman, S (1984). Impaired noradrenergic transmission in schizophrenia? A minireview. Life Sci, 34,1403PubMedCrossRefGoogle Scholar
  3. 3.
    Linnoila, M, Ninan, PT, Scheinin, M, Waters, RN, Chang, W, Bartko, J and van Kammen, DP (1983). Reliability of norepinephrine and major monoamine metabolites measurements in CSF of schizophrenic patients. Arch Gen Psychiatry, 40,1290PubMedGoogle Scholar
  4. 4.
    Matussek, N, Ackenheil, M, Hippius, H, Mueller, F, Schroder, HT, Shultes, H and Wasilewski, B (1980). Effect of Clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res, 2,25PubMedCrossRefGoogle Scholar
  5. 5.
    Kafka, MS, Siever, LJ, Nürnberger, JI, Uhde, TW, Targum, S, Cooper, DMJ, van Kammen, DP and Tokola, (1985). Platelet alpha-adrenergic receptor function in affective disorders and schizophrenia. Psychopharmacol Bull, 21,599PubMedGoogle Scholar
  6. 6.
    Pandey, GN, Garver, DL, Tamminga, CA, Ericksen, S, Ali, SI and Davis, JM (1977). Postsynaptic supersensitivity in schizophrenia. Am J Psychiatry, 134,518PubMedGoogle Scholar
  7. 7.
    Sternberg, DE, van Kammen, DP, Lake, CR, Marder, SR and Bunney, WE, Jr. (1981). The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry, 138, 1045PubMedGoogle Scholar
  8. 8.
    Ko, GN, Unnerstall, JR, Kuhar, MJ, Wyatt, RJ and Kleinman, JE (1986). Alpha-2 adrenergic agonist binding in schizophrenic brains. Psychopharmacol Bull, 22,1011Google Scholar
  9. 9.
    Mller-Spahn, F, Ackenheil, M, Albus, M, Botschev, C, Naber, D and Welter, D (1986). Neuroendocrine effects of Clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology. Psychopharmacology, 88,190CrossRefGoogle Scholar
  10. 10.
    Gattaz, WF, Riederer, P, Reynolds, GP, Gattaz, D and Beckman, H (1983). Dopamine and noradrenaline in cerebrospinal fluid of schizophrenic patients. Psychiatry Res, 8,243PubMedCrossRefGoogle Scholar
  11. 11.
    Lake, CR, Sternberg, D, van Kammen, DP, Ballenger, JC, Ziegler, MG, Post, RM, Kopin, IJ and Bunney, WE, Jr. (1980). Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science, 207,331PubMedCrossRefGoogle Scholar
  12. 12.
    Herz, MI, Szymanski, HV and Simon, JC (1982). Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry, 139, 918PubMedGoogle Scholar
  13. 13.
    Szymanski, HV, Simon, JC and Gutterman, N (1983). Recovery from schizophrenia psychosis. Am J Psychiatry, 140,381Google Scholar
  14. 14.
    Docherty, JP, van Kammen, DP, Siris, SG and Marder, SR (1978). Stages of onset of schizophrenic psychosis. Am J Psychiatry, 135,420PubMedGoogle Scholar
  15. 15.
    Crow, TJ (1980). Molecular pathology of schizophrenia: more than one disease process? Br Med J, 280,66PubMedCrossRefGoogle Scholar
  16. 16.
    van Kammen, DP, Rosen, J, Peters, J, Fields, R and van Kammen, WB (1985). Are there state dependent markers in schizophrenia? Psychopharmacol Bull, 21,497PubMedGoogle Scholar
  17. 17.
    King, R, Barchas, JD and Huberman, BA (1984). Chaotic behavior in dopamine neurodynamics. Proc Natl Acad Sci USA, 81,1244PubMedCrossRefGoogle Scholar
  18. 18.
    Kemali, D, Maj, M, Iorio, G, Marciano, F, Nolfe, G, Galderisi, S and Salvati, A (1985). Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients. Acta Psychiatr. Scand., 71,19PubMedCrossRefGoogle Scholar
  19. 19.
    Monti, JM (1983). Catecholamines and the sleep-wake cycle. II. REM sleep. Life Sci, 32, 1401PubMedCrossRefGoogle Scholar
  20. 20.
    van Kanmmen, DP, van Kammen, WB, Peters, JL, Rosen, J, Slawsky, RC, Neylan, TC, Linnoila, M (1986). CSF MHPG, sleep and psychosis in schizophrenia. Clin Neuropharm, 9, suppl. 4,575Google Scholar
  21. 21.
    van Kammen, DP, Bunney, WE, Jr., Docherty, JP, Marder, SR, Eberg, MH, Rosenblatt, JE and Rayner, JN (1982). d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophreniz. Am J Psychiatry, 139,991PubMedGoogle Scholar
  22. 22.
    Bowers, MB, Jr., Swigar, ME, Jatlow, PI, Hoffman, F and Giocoechea, N (1986). Early neuroleptic response in psychotic men and women: correlation with plasma HVA and MHPG. Comp Psychiatry, 27,181CrossRefGoogle Scholar

Copyright information

© MTP Press Limited 1987

Authors and Affiliations

  • D. P. van Kammen
  • T. C. Neylan
  • W. B. van Kammen
  • J. L. Peters
  • J. Rosen
  • M. Linnoila

There are no affiliations available

Personalised recommendations